Literature DB >> 33403040

Hypoxia Inducible Factor-1alpha (HIF-1A) plays different roles in Gallbladder Cancer and Normal Gallbladder Tissues.

Youliang Wu1, Delong Meng2, Yexiang You1, Ruochuan Sun1, Min Fu1, Qiang Yan1, Shangxin Zhang1, Zheng Fang1, Junjun Bao1, Yongxiang Li1.   

Abstract

Purpose: an class="Gene">Hypoxia-inducible factor-1alpha (HIF-1A) is a transcription factor that plays an "angiogenic switch" role especially under hypoxia microenvironment in solid tumor. However, the functions and clinical significance of HIF-1A in gallbladder cancer (GBC) are still controversial, and it has not been studied in normal gallbladder tissues. In this study, we sought to clarify the role of sub-cellular localization of HIF-1A expression in GBC and normal gallbladder tissues.
Methods: The expressions of HIF-1A and CD34 in 127 GBC and 47 normal gallbladder tissues were evaluated by immunohistochemistry. Cox's proportional hazards model analysis and Kaplan-Meier method analysis were used to assess the correlations between these factors and clinicopathological features and prognosis.
Results: HIF-1A was expressed in both cytoplasm and nucleus of GBC and normal control tissues, and was significantly correlated with microvessel density (MVD). GBC tissues with positive nuclear HIF-1A expression had higher MVD compared to that with positive cytoplasmic HIF-1A expression; however, in normal gallbladder tissues, samples with positive cytoplasmic HIF-1A had higher MVD compared to that with positive nuclear HIF-1A expression. Moreover, GBC with nuclear HIF-1A expression tended to be more poorly differentiated and had larger tumor size compared to that with cytoplasm HIF-1A expression. Furthermore, GBC patients with nuclear HIF-1A positive were significantly correlated with worse overall survival (OS) compared with cytoplasmic HIF-1A positive. Multivariate Cox regression analysis identified lymph node metastasis and nuclear HIF-1A expression to be independent prognostic parameter in GBC. Conclusions: Our findings provide evidence for the first time that HIF-1A is expressed in normal gallbladder tissues. Nuclear HIF-1A and cytoplasm HIF-1A plays different roles in GBC and normal gallbladder tissues. © The author(s).

Entities:  

Keywords:  HIF-1A; MVD; gallbladder cancer; normal gallbladder tissue; prognosis bio-marker

Year:  2021        PMID: 33403040      PMCID: PMC7778542          DOI: 10.7150/jca.46749

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  47 in total

Review 1.  Gallbladder cancer.

Authors:  Mislav Rakić; Leonardo Patrlj; Mario Kopljar; Robert Kliček; Marijan Kolovrat; Bozo Loncar; Zeljko Busic
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Proteome Analysis of Hypoxic Glioblastoma Cells Reveals Sequential Metabolic Adaptation of One-Carbon Metabolic Pathways.

Authors:  Kangling Zhang; Pei Xu; James L Sowers; Daniel F Machuca; Barsam Mirfattah; Jason Herring; Hui Tang; Yan Chen; Bing Tian; Allan R Brasier; Lawrence C Sowers
Journal:  Mol Cell Proteomics       Date:  2017-09-05       Impact factor: 5.911

3.  A tumoural angiogenic gateway blocker, Benzophenone-1B represses the HIF-1α nuclear translocation and its target gene activation against neoplastic progression.

Authors:  Prabhu Thirusangu; V Vigneshwaran; V Lakshmi Ranganatha; B R Vijay Avin; Shaukath Ara Khanum; Riaz Mahmood; K Jayashree; B T Prabhakar
Journal:  Biochem Pharmacol       Date:  2016-11-09       Impact factor: 5.858

4.  Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis.

Authors:  R H Giles; M P Lolkema; C M Snijckers; M Belderbos; P van der Groep; D A Mans; M van Beest; M van Noort; R Goldschmeding; P J van Diest; H Clevers; E E Voest
Journal:  Oncogene       Date:  2006-05-18       Impact factor: 9.867

Review 5.  Improvement in the diagnosis and treatment of T2 gallbladder carcinoma is pivotal to improvement in the overall prognosis for this disease.

Authors:  Di Zhou; Jiandong Wang; Zhiwei Quan; Yong Yang; Fei Ma
Journal:  Biosci Trends       Date:  2019       Impact factor: 2.400

6.  Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis.

Authors:  Yanislav Kolev; Hiroyuki Uetake; Yoko Takagi; Kenichi Sugihara
Journal:  Ann Surg Oncol       Date:  2008-06-03       Impact factor: 5.344

7.  Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression.

Authors:  Claudio Di Cristofano; Andrea Minervini; Michele Menicagli; Giuseppe Salinitri; Gloria Bertacca; Gerasimos Pefanis; Lorenzo Masieri; Francesca Lessi; Paola Collecchi; Riccardo Minervini; Marco Carini; Generoso Bevilacqua; Andrea Cavazzana
Journal:  Am J Surg Pathol       Date:  2007-12       Impact factor: 6.394

8.  The investigation of tumoral angiogenesis with HIF-1 alpha and microvessel density in women with endometrium cancer.

Authors:  Aysun Aybatlı; Cenk Sayın; Petek Balkanlı Kaplan; Füsun Varol; Semsi Altaner; Necdet Süt
Journal:  J Turk Ger Gynecol Assoc       Date:  2012-03-01

9.  Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.

Authors:  Lupeng Li; Lixiang Wang; Ping Song; Xue Geng; Xiuming Liang; Minran Zhou; Yangyang Wang; Chunyan Chen; Jihui Jia; Jiping Zeng
Journal:  Mol Cancer       Date:  2014-04-09       Impact factor: 27.401

10.  The estrogen receptor variants β2 and β5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling.

Authors:  Michelle Faria; Peter Shepherd; Yinghong Pan; Sujash S Chatterjee; Nora Navone; Jan-Åke Gustafsson; Anders Strom
Journal:  Oncotarget       Date:  2018-11-20
View more
  1 in total

1.  Quantification of the Landscape for Revealing the Underlying Mechanism of Intestinal-Type Gastric Cancer.

Authors:  Chong Yu; Jin Wang
Journal:  Front Oncol       Date:  2022-05-03       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.